Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure

Kidney International

Volumn 56, Issue 3, 1999, Pages 898-909

  Noda, Masakuni ^a,b   Matsuo, Takanori ^a   Fukuda, Ryo ^a   Ohta, Masayuki ^a   Nagano, Hiroko ^a   Shibouta, Yumiko ^a   Naka, Takehiko ^a   Nishikawa, Kohei ^a   Imura, Yoshimi ^a  

^a Research Management Department   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

ACE inhibitor; Angiotensin II receptor antagonist; Injury; Nephrectomy; Progressive renal disease; Renoprotection

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; NEPHRECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0032883825     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00614.x     Document Type: Article

References (44)

1. 1. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
2. 2. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
3. 3. Matsusaka T, Hymes J, Ichikawa I: Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol 7:2025-2043, 1996
4. 4. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
5. 5. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
6. 6. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV-116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 12(Suppl 9):S11-S16, 1994
7. 7. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
8. 8. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
9. 9. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ: Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 267:657-663, 1993
10. 10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
11. 11. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
12. 12. Camprell DJ, Kladis A, Valentijn AJ: Effects of losartan on angiotensin and bradykinin peptide and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26:233-240, 1995
13. 13. Dzau VJ, Muroyama M, Pratt RE: Molecular biology of angiotensin receptor: Target for drug research? J Hypertens 12(Suppl 2):S1-S5, 1994
14. 14. Gavras I: Bradykinin-mediated effects of ACE inhibition. Kidney Int 42:1020-1029, 1992
15. 15. Campbell DJ, Kladis A, Duncan AM: Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449, 1994
16. 16. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926-1935, 1997
17. 17. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G: Evidence that an angiotensin-converting enzyme inhibitor has different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5:1139-1146, 1994
18. 18. Verseput GH, Provoost AP, Braam BB, Weening JJ, Koomans HA: Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawnhooded rat. J Am Soc Nephrol 8:249-259, 1997
19. 19. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K: Angiotensin II receptor antagonistic action of candesartan (CV-11974) in the rabbit aorta. Jpn Pharmacol Ther 24:121-126, 1996
20. 20. Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T: Nonpeptide angiotensin II receptor antagonists: Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 36: 2343-2349, 1993
21. 21. Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T, Nishikawa K: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist (±)-1-(cyclohexyloxycarbonyloxy) ethyl2-ethoxy-1-[[2′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 268:1540-1547, 1994
22. 1-receptor antagonist, in conscious spontaneously hypertensive rats. Jpn J Pharmacol 73:185-190, 1997
23. 23. Powell WS: Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandin 20:947-957, 1980
24. 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51:1553-1567, 1997
25. 25. El-Dahr SS, Dipp S, Yosipiv IV, Baricos W: Bradykinin stimulates c-fos expression, AP-1-DNA binding activity and proliferation of rat glomerular mesangial cells. Kidney Int 50:1850-1855, 1996
26. 1 is mediated by the AP-1 complex. Mol Cell Biol 10:1492-1497, 1990
27. 27. Cooper CL, Malik KU: Evidence that bradykinin stimulates renal prostaglandin synthesis by a mechanism distinct from that of other vasoactive substances. Circ Res 60:914-922, 1987
28. 28. Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilatation during angiotensin 1 converting enzyme inhibition. Kidney Int 44:545-550, 1993
29. 29. Ichikawa I: Will angiotensin II receptor antagonists be renoprotective in human? Kidney Int 50:684-692, 1996
30. 30. Nishimura H, Hoffmann S, Baltatu O, Sugimura K, Ganten D, Urata H: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int 49(Suppl 55):S18-S23, 1996
31. 31. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 80:219-227, 1997
32. 32. Urata H, Strobel F, Ganten D: Widespread tissue distribution of human chymase. J Hypertens 12(Suppl 9):S17-S22, 1994
33. 33. Wintroub BU, Klickstein LB, Dzau VJ, Watt WK: Granulocyte angiotensin system: Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry 23:227-232, 1984
34. 2) receptor protein in rat kidney. Kidney Int 30:1238-1246, 1997
35. 35. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RAK: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: Role of the angiotensin type 2 receptor. J Clin Invest 100:1047-1058, 1997
36. 36. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92:2597-2601, 1993
37. 1 develop progressive renal disease. Lab Invest 74:991-1003, 1996
38. 38. Egido J: Vosoactive hormones and renal sclerosis. Kidney Int 49: 578-597, 1996
39. 39. Floege J, Eng E, Young BA, Johnson RJ: Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int 43(Suppl):S47-S54, 1993
40. 40. Muchaneta-Kubara EC, Sayed-Ahmed N, Nahas AM: Subtotal nephrectomy: A mosaic of growth factors. Nephrol Dial Transplant 10:320-327, 1995
41. 1 during glomerulosclerosis in rats with reduced renal mass. Clin Exp Nephrol 1:187-194, 1997
42. 42. Gasc JM, Monnot C, Clauser E, Corvol P: Co-expression of type 1 angiotensin II receptor (ATIR) and renin mRNAs in juxtaglomerular cells of rat kidney. Endocrinology 132:2723-2725, 1993
43. 43. Griffin KA, Picken M, Bidani AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4:1023-1031, 1994
44. 44. Taal MW, Brenner BM: ACE-I vs angiotensin II receptor antagonists: Prevention of renal injury in chronic rat models. J Hum Hypertens 13(Suppl 1):S51-S56, 1999